A fifty-year odyssey: prospects for a cytomegalovirus vaccine in transplant and congenital infection.

ABSTRACT:

Introduction

It has been almost fifty years since the Towne strain was used by Plotkin and collaborators as the first vaccine candidate for cytomegalovirus (CMV). While that approach showed partial efficacy, there have been a multitude of challenges to improve on the promise of a CMV vaccine. Efforts have been dichotomized into a therapeutic vaccine for patients with CMV-infected allografts, either stem cells or solid organ, and a prophylactic vaccine for congenital infection.

Areas covered

This review will evaluate research prospects for a therapeutic vaccine for transplant recipients that recognizes CMV utilizing primarily T cell responses. Similarly, we will provide an extensive discussion on attempts to develop a vaccine to prevent the manifestations of congenital infect

SUBMITTER: Diamond DJ 

PROVIDER: S-EPMC6343505 | biostudies-literature | 2018 Oct

REPOSITORIES: biostudies-literature